SIGA Technologies Inc
NASDAQ:SIGA
Intrinsic Value
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. [ Read More ]
The intrinsic value of one SIGA stock under the Base Case scenario is 12.91 USD. Compared to the current market price of 8.56 USD, SIGA Technologies Inc is Undervalued by 34%.
Valuation Backtest
SIGA Technologies Inc
Run backtest to discover the historical profit from buying and selling SIGA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of SIGA Technologies Inc's business.
What risks and challenges
does SIGA Technologies Inc face in the near future?
Summarize the latest earnings report
of SIGA Technologies Inc.
Provide P/E
for SIGA Technologies Inc and its competitors.
Balance Sheet Decomposition
SIGA Technologies Inc
Current Assets | 239m |
Cash & Short-Term Investments | 150.1m |
Receivables | 21.1m |
Other Current Assets | 67.7m |
Non-Current Assets | 15.4m |
PP&E | 1.3m |
Intangibles | 898.3k |
Other Non-Current Assets | 13.1m |
Current Liabilities | 54.1m |
Accounts Payable | 1.5m |
Accrued Liabilities | 7.5m |
Other Current Liabilities | 45.1m |
Non-Current Liabilities | 3.4m |
Other Non-Current Liabilities | 3.4m |
Earnings Waterfall
SIGA Technologies Inc
Revenue
|
139.9m
USD
|
Cost of Revenue
|
-17.2m
USD
|
Gross Profit
|
122.7m
USD
|
Operating Expenses
|
-38.5m
USD
|
Operating Income
|
84.2m
USD
|
Other Expenses
|
-16.2m
USD
|
Net Income
|
68.1m
USD
|
Free Cash Flow Analysis
SIGA Technologies Inc
What is Free Cash Flow?
SIGA Profitability Score
Profitability Due Diligence
SIGA Technologies Inc's profitability score is 80/100. The higher the profitability score, the more profitable the company is.
Score
SIGA Technologies Inc's profitability score is 80/100. The higher the profitability score, the more profitable the company is.
SIGA Solvency Score
Solvency Due Diligence
SIGA Technologies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
SIGA Technologies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIGA Price Targets Summary
SIGA Technologies Inc
According to Wall Street analysts, the average 1-year price target for SIGA is 17.88 USD with a low forecast of 17.71 USD and a high forecast of 18.41 USD.
Ownership
SIGA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SIGA Price
SIGA Technologies Inc
Average Annual Return | 8.48% |
Standard Deviation of Annual Returns | 30.05% |
Max Drawdown | -82% |
Market Capitalization | 608.5m USD |
Shares Outstanding | 71 091 600 |
Percentage of Shares Shorted | 11.19% |
SIGA News
Last Important Events
SIGA Technologies Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
SIGA Technologies Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
Contact
IPO
Employees
Officers
The intrinsic value of one SIGA stock under the Base Case scenario is 12.91 USD.
Compared to the current market price of 8.56 USD, SIGA Technologies Inc is Undervalued by 34%.